Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Selective dopamine D3 receptor modulators synthesized at SB

Jan. 18, 1999

SmithKline Beecham describes novel compounds for depression and other CNS disorders

Jan. 18, 1999

CLASS study evaluates clomethiazole in acute stroke patients

Jan. 18, 1999

Dopamine D3 antagonists for psychoses and other D3 ligands designed at SmithKline Beecham

Jan. 15, 1999

Urea derivatives acting at multiple 5-HT receptor subtypes emerge from SB R&D

Jan. 15, 1999

Indole-based antimigraine agents in development at Allelix

Jan. 15, 1999

CPMP recommends approval of higher dosage form of Rebif

Jan. 14, 1999

German academics uncover hormonal mechanism involved in sleep-wake cycles

Jan. 14, 1999

Substance P antagonist reduces pain in dental surgery patients

Jan. 14, 1999

FDA advisory committee reaches positive conclusions regarding Chirocaine

Jan. 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...